A Day Inside a Day-Care Chemotherapy Unit: What Modern Cancer Care Looks Like

A Day Inside a Day-Care Chemotherapy Unit: What Modern Cancer Care Looks Like

By Dr. Viraj Nevrekar

A day-care chemotherapy unit is not simply a room where an intravenous drug is administered. A treatment visit usually involves several clinical checkpoints: confirming that the planned regimen is still appropriate, reviewing recent toxicities, checking laboratory results, preparing the prescribed medicines, administering premedication and anticancer therapy, monitoring for immediate reactions, and deciding whether the patient can safely return home.

For many patients, this entire process happens within a few hours. Understanding what takes place behind the scenes can make a chemotherapy day far less mysterious.

Before Leaving Home: The Chemotherapy Day Has Already Started

Patients are usually given instructions specific to their regimen before arriving at the unit. Depending on the treatment, these may cover eating and drinking, medicines to take at home, blood tests, and what symptoms must be reported before treatment.

One practical point matters more than many patients realise: do not wait until the infusion begins to mention a new symptom.

A fever since the previous cycle, persistent diarrhoea, repeated vomiting, worsening numbness in the hands or feet, mouth ulcers that make eating difficult, unusual bleeding, breathlessness or markedly reduced urine output can influence the day's treatment decision.

This does not automatically mean chemotherapy will be cancelled. It means the oncology team needs the information before proceeding.

Arrival: Why Chemotherapy Does Not Always Start Immediately

After registration, patients may expect the intravenous line to be inserted and chemotherapy to begin.

Modern day-care oncology usually has several checks before that point.

The team needs to establish that the patient arriving today is clinically suitable for the treatment that was planned earlier. Cancer treatment is prescribed as a regimen, often organised into treatment cycles, but the prescription is not considered in isolation from what has happened to the patient since the previous cycle.

A nurse or clinician may therefore ask about:

  • fever or recent infection

  • nausea, vomiting or diarrhoea

  • oral ulcers or difficulty swallowing

  • appetite and fluid intake

  • constipation

  • new pain

  • numbness, tingling or weakness

  • bleeding or bruising

  • breathlessness

  • fatigue and ability to perform normal activities

  • problems experienced after the previous cycle

  • new medicines or hospital admissions

These questions are not administrative formalities. They are part of toxicity assessment.

For example, worsening peripheral neuropathy may matter considerably for a regimen containing a neurotoxic drug. Persistent diarrhoea may raise concerns about dehydration and electrolyte disturbance. A recent infection becomes particularly relevant if bone marrow recovery is incomplete.

The Blood Test Checkpoint

One of the most familiar parts of chemotherapy day is the blood test.

A complete blood count may include haemoglobin, platelet count and the absolute neutrophil count, or ANC. Depending on the chemotherapy regimen, clinicians may also assess kidney function, liver function and electrolytes.

Why?

Many cytotoxic chemotherapy drugs damage rapidly proliferating cancer cells, but normal tissues containing dividing cells can also be affected. Bone marrow continuously produces blood cells from precursor cells. Suppression of these precursors can lead to myelosuppression.

A reduced neutrophil count can increase susceptibility to infection. Low platelets can increase bleeding risk. Anaemia can contribute to fatigue, weakness and breathlessness.

Kidney and liver results matter for a different reason. These organs participate in the metabolism or elimination of many anticancer medicines. Significant organ dysfunction may alter drug exposure or increase toxicity with certain agents.

But there is no single laboratory number that universally decides whether chemotherapy proceeds.

The oncologist considers the regimen, degree of abnormality, previous toxicity, current clinical condition, treatment intent and protocol-specific requirements. Sometimes treatment proceeds as planned. In other circumstances, the cycle may be delayed or the dose modified.

A treatment delay is therefore not the same thing as treatment failure. It may simply allow recovery from toxicity before the next exposure.

The Prescription Goes Through Multiple Checks

If treatment is going ahead, another process occurs that patients may barely notice. Chemotherapy is a high-risk medication and requires careful verification.

Depending on the centre and regimen, checks may include the patient's identity, cancer diagnosis, treatment protocol, drug, calculated dose, route of administration, cycle number and relevant laboratory parameters.

Some chemotherapy doses are calculated using body surface area, while other systemic anticancer medicines use different dosing approaches. Previous dose reductions or treatment modifications also need to be carried forward correctly.

The pharmacy then prepares the prescribed treatment according to appropriate handling procedures. This is one reason chemotherapy cannot always be prepared like an ordinary intravenous medication immediately after a patient arrives.

Before Chemotherapy: Why Other Medicines May Be Given First

Patients are sometimes surprised when the first infusion bag is not chemotherapy.

Premedication may be administered before particular regimens. Its purpose depends on the drugs being used.

For some treatments, medicines are given to reduce chemotherapy-induced nausea and vomiting. Other regimens require premedication intended to reduce the likelihood or severity of infusion-related or hypersensitivity reactions. Hydration may be required with selected drugs.

The exact combination varies substantially.

Not every chemotherapy drug causes the same degree of nausea. Not every regimen requires extensive hydration. Not every patient receives the same premedication.

This is why comparing infusion-day medicines with another patient's treatment can be misleading even when both patients describe themselves as "having chemotherapy."

The Infusion Begins

Chemotherapy may be administered through a peripheral intravenous cannula or, in patients who require repeated or particular intravenous treatments, through a central venous access device such as an implanted port or another suitable catheter.

The duration varies dramatically.

One drug may be administered relatively quickly. Another may require a prolonged infusion. Combination regimens can involve several medicines given sequentially, with fluids or supportive medicines between them.

During administration, nurses monitor the patient and the intravenous access.

A patient should tell the nurse promptly about new symptoms such as burning or pain around the cannula, swelling, flushing, itching, chest discomfort, breathlessness, dizziness or an abrupt feeling of being unwell.

Some symptoms can indicate an infusion-related reaction. Pain or swelling around a peripheral intravenous site can also raise concern about leakage of medication outside the vein, known as extravasation. The clinical significance depends heavily on the drug involved.

Prompt reporting allows the team to assess what is happening rather than waiting for symptoms to become severe.

Why Some Patients Sleep Through Treatment While Others Are Closely Watched

The person in the next chemotherapy chair may be receiving a completely different treatment.

One patient may have an uncomplicated infusion and spend most of the session reading or sleeping. Another may need closer observation because of the medicine being administered, a previous reaction or specific clinical concerns.

Even patients with the same cancer may receive different regimens because treatment depends on factors such as disease subtype, stage, molecular characteristics, previous treatment and treatment objective.

The objective itself also matters.

Chemotherapy may be given before surgery to reduce tumour burden, after local treatment to reduce recurrence risk, concurrently with radiotherapy, as part of treatment intended to cure certain cancers, or to control advanced disease and reduce cancer-related symptoms.

The physical setting may look similar, but the clinical purpose of treatment can be very different.

What Happens When the Infusion Finishes?

Finishing the last infusion bag does not necessarily mean the clinical work is over.

The intravenous line or access device is managed appropriately, and the patient may be observed if the regimen requires it. Instructions for medicines to be taken at home may be reviewed, along with the date of the next blood test, consultation or treatment cycle.

This is also the time to clarify what should trigger a call to the oncology team.

Chemotherapy toxicity does not necessarily peak while the patient is sitting in the day-care unit.

Bone marrow suppression, for example, can develop after treatment as affected precursor cells decline and circulating cells subsequently fall. Mouth ulcers, diarrhoea, fatigue and other adverse effects may also emerge later.

Patients should therefore know whom to contact if symptoms develop between cycles.

Fever during chemotherapy deserves particular attention because neutropenia can reduce the body's capacity to respond normally to infection. Fever with neutropenia can represent febrile neutropenia, a potentially serious complication requiring prompt medical assessment.

Patients should follow the temperature and emergency instructions given by their own oncology unit rather than waiting until the next scheduled appointment.

Leaving the Unit: Treatment Continues Beyond the Chair

Once medically cleared to leave, many patients return home the same day.

That is what makes day-care chemotherapy possible, but "day care" should not be confused with minor treatment.

The anticancer drug continues exerting biological effects after the infusion has ended. The oncology team therefore evaluates what happens between visits as carefully as what happens inside the unit.

Keeping track of significant symptoms can be useful before the next cycle. Rather than saying only, "I felt very weak," it is more clinically informative to explain when the weakness started, how long it lasted, whether eating and drinking were affected, whether there was fever, and whether normal activities became difficult.

Those details can help clinicians grade toxicity and judge how well the treatment is being tolerated.

What Modern Day-Care Chemotherapy Really Involves

The most visible part of chemotherapy is the infusion. Much of the safety system sits around it.

The blood test checks whether the body has recovered sufficiently. The clinical review looks for toxicities that laboratory results may not reveal. Pharmacy verification helps ensure the intended regimen and dose are prepared correctly. Nursing assessment provides surveillance during administration. Follow-up instructions extend monitoring into the days after the patient leaves.

For patients travelling repeatedly to cancer centres in India, sometimes over considerable distances, the practical burden of these visits can be significant. Knowing the sequence beforehand helps families plan transport, meals, medicines, reports and time away from work more realistically.

A modern day-care chemotherapy unit is therefore best understood not as an infusion facility, but as a coordinated clinical system. The medicine entering the intravenous line is only one part of the treatment day. The decisions made before, during and after that infusion are equally important to delivering systemic anticancer therapy safely.
Watch this short video to know how a day at ICTC Cancer Day Care usually goes. Link to Instagram.

About the Author

Dr. Viraj Nevrekar

Dr. Viraj Nevrekar

MD Internal Medicine (AIIMS), DM Medical Oncology (AIIMS), MRCP (UK) Certified, ESMO Certified Oncologist

Dr. Viraj Nevrekar is a highly experienced Cancer Specialist and Medical Oncologist with over 16 years of clinical experience in the field of oncology. He is known for delivering advanced, evidence-based, and compassionate cancer care to patients across a wide range of malignancies. Dr. Nevrekar has served as a Consultant Medical Oncologist at several reputed healthcare institutions, including Holy Family Hospital, Holy Spirit Hospital, and Millat Nursing Home. Through his work at these centres, he has gained extensive exposure to complex oncology cases and has developed strong expertise in chemotherapy, immunotherapy, and targeted therapy for solid tumors and hematological cancers. Academically, Dr. Nevrekar holds an MBBS, MD in Internal Medicine, and DM in Medical Oncology from the All India Institute of Medical Sciences (AIIMS), New Delhi. His rigorous training at AIIMS provided a strong foundation in protocol-driven oncology care, multidisciplinary cancer management, and advanced therapeutic techniques. He is also certified by the European Society of Medical Oncology (ESMO), ensuring alignment with global oncology standards and best practices. Clinically, Dr. Nevrekar specializes in the management of gastrointestinal, breast, head and neck, and ovarian cancers. His expertise extends to advanced chemotherapy, molecular targeted therapy, and immunotherapy, enabling him to deliver personalized cancer treatment based on tumor biology and patient- specific factors. Dr. Nevrekar is highly regarded for his patient-centric approach, combining scientific accuracy with empathy and clear communication. He focuses on designing individualized treatment plans that not only aim for disease control and cure but also prioritize quality of life and long-term well-being. In addition to his clinical work, Dr. Nevrekar has actively contributed to oncology research. He has authored and co-authored research publications focusing on chemotherapy, targeted therapy, and immunotherapy. His academic contributions provide valuable insights into modern cancer treatment strategies and support evidence-based oncology practice. Over the years, Dr. Viraj Nevrekar has been acknowledged for his dedication to oncology, receiving recognition for his clinical excellence, innovative therapeutic approaches, and meaningful contributions to improving patient care through advanced medical practice and research.